Humana (NYSE:HUM) Receives Neutral Rating from Cantor Fitzgerald

Humana (NYSE:HUM)‘s stock had its “neutral” rating reiterated by Cantor Fitzgerald in a report issued on Friday, Benzinga reports. They currently have a $395.00 target price on the insurance provider’s stock. Cantor Fitzgerald’s target price points to a potential upside of 27.31% from the stock’s previous close.

HUM has been the topic of a number of other research reports. Piper Sandler assumed coverage on shares of Humana in a research note on Wednesday, June 26th. They set an “overweight” rating and a $392.00 target price on the stock. Royal Bank of Canada boosted their target price on shares of Humana from $385.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, September 5th. Baird R W raised shares of Humana to a “hold” rating in a research note on Thursday, May 30th. Morgan Stanley initiated coverage on Humana in a report on Monday, June 24th. They set an “equal weight” rating and a $374.00 target price on the stock. Finally, Truist Financial increased their price target on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research note on Monday, July 15th. Thirteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Humana presently has a consensus rating of “Hold” and an average price target of $398.70.

Humana Price Performance

Shares of HUM stock traded down $1.74 during trading on Friday, hitting $310.26. The company had a trading volume of 338,528 shares, compared to its average volume of 1,631,401. The stock’s 50-day moving average price is $359.14 and its 200 day moving average price is $345.90. Humana has a one year low of $298.61 and a one year high of $530.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The firm has a market capitalization of $37.39 billion, a P/E ratio of 19.32, a price-to-earnings-growth ratio of 2.56 and a beta of 0.50.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. Humana’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm posted $8.94 EPS. Equities analysts expect that Humana will post 16 EPS for the current fiscal year.

Institutional Trading of Humana

Several institutional investors and hedge funds have recently bought and sold shares of the company. Brown Advisory Inc. lifted its stake in Humana by 17.9% in the fourth quarter. Brown Advisory Inc. now owns 2,724 shares of the insurance provider’s stock worth $1,247,000 after purchasing an additional 413 shares during the last quarter. Trexquant Investment LP purchased a new stake in Humana during the 4th quarter valued at about $2,099,000. Quest Partners LLC purchased a new position in Humana in the 4th quarter worth approximately $128,000. Assetmark Inc. lifted its position in Humana by 4.0% in the fourth quarter. Assetmark Inc. now owns 6,840 shares of the insurance provider’s stock valued at $3,131,000 after purchasing an additional 263 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in shares of Humana by 12.3% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 10,323 shares of the insurance provider’s stock valued at $4,726,000 after purchasing an additional 1,127 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.